Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin a, MS-209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP

Anti-Cancer Drugs

Volumn 8, Issue 2, 1997, Pages 141-155

  Germann, Ursula A ^a   Ford, Pamella J ^a   Shlyakhter, Dina ^a   Mason, Valerie S ^a   Harding, Matthew W ^a  

^a VERTEX PHARMACEUTICALS   (United States)

Author keywords

Chemosensitizer; Cyclosporin A; GF120918; MS 209; Multidrug resistance associated protein; P glycoprotein; Verapamil; VX 710

Indexed keywords

5 [3 (4 DIPHENYLACETYL 1 PIPERAZINYL) 2 HYDROXYPROPOXY]QUINOLINE; ANTINEOPLASTIC AGENT; BIRICODAR; CALCEIN; CYCLOSPORIN A; DAUNORUBICIN; DOXORUBICIN; ELACRIDAR; ETOPOSIDE; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE REVERSING AGENT; RADIOISOTOPE; UNCLASSIFIED DRUG; VERAPAMIL; VF 13159; VINCRISTINE;

ARTICLE; CANCER CELL CULTURE; CELL STRAIN HL 60; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACCUMULATION; GENE EXPRESSION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PHOTOAFFINITY LABELING; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA;

EID: 0031041043     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199702000-00005     Document Type: Article

References (63)

1. Lehnert M. Clinical multidrug resistance in cancer - a multifactorial problem. Eur J Cancer 1996; 32A: 912-20.
2. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976; 455: 152-62
3. Cole SPC, Bhardwaj G, Gerlach JH, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992; 258: 1650-4.
4. Higgins CF. The ABC transporter channel superfamily - an overview. Semin Cell Biol 1993; 4: 1-5.
5. Ames GF-L, Mimura CS, Holbrook SR, Shyamala V. Traffic ATPases: a superfamily of transport proteins operating from Escherichia coli to humans. Adv Enzymol 1992; 65: 1-47.
6. Germann UA. P-glycoprotein - a mediator of multidrug resistance in tumour cells. Eur J Cancer 1996; 32A: 927-44.
7. Loe DW, Deeley RG, Cole SPC. Biology of the multidrug resistance-associated protein. MRP. Eur J Cancer 1996; 32A: 945-57.
8. Cole SP, Sparks KE, Fraser K, et al. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res 1994; 54: 5902-10.
9. Zaman GJ, Flens MJ, van Leusden MR, et al. The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc Natl Acad Sci USA 1994; 91: 8822-6.
10. Breuninger LM, Paul S, Gaughan K, et al. Expression of multidrug resistance-associated protein in NIH/3T3 cells confers multidrug resistance associated with increased drug efflux and altered intracellular drug distribution. Cancer Res 1995; 55: 5342-7.
11. Brock I, Hipfner DR, Nielsen BS, et al. Sequential coexpression of the multidrug resistance genes MRP and mdr1 and their products in VP-16 (etoposide)-selected H60 small cell lung cancer cells. Cancer Res 1995; 55: 459-62.
12. Slapak CA, Mizunuma N, Kufe DW. Expression of the multidrug resistance associated protein and P-glycoprotein in doxorubicin-selected human myeloid leukemia cells. Blood 1994; 84: 3113-21.
13. Hasegawa S, Abe T, Naito S, et al. Expression of multidrug resistance-associated protein (MRP), MDR1 and DNA topoisomerase II in human multidrug-resistant bladder cancer cell lines. Br J Cancer 1995; 71: 907-13.
14. Danø K. Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells. Biochem Biophys Acta 1973; 323: 466-83.
15. Ling V, Thompson LH. Reduced permeability in CHO cells as a mechanism of resistance to colchicine. J Cell Physiol 1974; 83: 103-16.
16. McGrath T, Center MS. Mechanisms of multidrug resistance in HL60 cells: evidence that a surface membrane protein distinct from P-glycoprotein contributes to reduced cellular accumulation of drug. Cancer Res 1988; 48: 3959-63.
17. Shapiro AB, Ling V. Reconstitution of drug transport by purified P-glycoprotein. J Biol Chem 1995; 270: 16167-75.
18. Schuurhuis GJ, Vanheijningen THM, Cervantes A, et al. Changes in subcellular doxorubicin distribution and cellular accumulation alone can largely account for doxorubicin resistance in SW-1573 lung cancer and MCf-7 breast cancer multidrug resistant tumour cells. Br J Cancer 1993; 68: 898-908.
19. Barrand MA, Rhodes T, Center MS, Twentyman PR. Chemosensitisation and drug accumulation effects of cyclosporin-A, PSC-833 and verapamil in human MDR large cell lung cancer cells expressing a 190k membrane protein distinct from P-glycoprotein. Eur J Cancer 1993; 29A: 408-15.
20. Marquardt D, Center MS. Drug transport mechanisms in HL60 cells isolated for resistance to adriamycin: evidence for nuclear drug accumulation and redistribution in resistant cells. Cancer Res 1992; 52: 3157-63.
21. Krishnamachary N, Center MS. Detection and characterization of membrane protein changes in multidrug resistant HL-60 cells. Oncol Res 1992; 4: 23 8.
22. Almquist KC, Loe DW, Hipfner DR, et al. Characterization of the M(r) 190,000 multidrug resistance protein (MRP) in drug-selected and transfected human tumor cell. Cancer Res 1995; 55: 102-10.
23. Hens MJ, Izquierdo MA, Scheffer GL, et al. Immunochemical detection of the multidrug resistance-associated protein MRP in human multidrug-resistant tumor cells by monoclonal antibodies. Cancer Res 1994; 54: 4557-63.
24. Barrand MA, Robertson KJ, Neo SY, et al. Localisation of the multidrug resistance-associated protein, MRP, in resistant large-cell lung tumour cells. Biochem Pharmacol 1995; 50: 1725-9.
25. Marie J-P, Zhou D-C, Gurbuxani S, Legrand O, Zittoun R. MDR1/P-glycoprotein in haematological neoplasms. Eur J Cancer 1996; 32A: 1034-8.
26. Goldstein LJ. MDR1 gene expression in solid tumours. Eur J Cancer 1996; 32A: 1039-50.
27. Nooter K, Bosnian FT, Burger H, et al. Expression of the multidrug resistance-associated protein (MRP) in human cancers. Ann Oncol 1996; 7: 75-81.
28. Sugawara I, Masunaga A, Itoyama S, et al. Expression of multidrug resistance-associated protein (MRP) in thyroid cancers. Cancer Lett 1995; 95: 135-8.
29. Norris MD, Bordow SB, Marshall GM, et al. Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma. N Engl J Med 1996; 334: 231-8.
30. Burger H, Nooter K, Zaman GJ, et al. Expression of the multidrug resistance-associated protein (MRP) in acute and chronic leukemias. Leukemia 1994; 8: 990-7.
31. Beck J, Handgretinger R, Dopfer R, et al. Expression of mdr 1,mrp, topoisomerase II alpha/beta, and cyclin A in primary or relapsed states of acute lymphoblastic leukaemias. Br J Haematol 1995; 89: 356-63.
32. Beck J, Niethammer D, Gekeler V. MDR1, MRP, topoisomerase II alpha/beta, and cyclin A gene expression in acute and chronic leukemias. Leukemia 1996; 10: S39-45.
33. Ford JM. Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitizers. Eur J Cancer 1996; 32A: 991-1001.
34. Twentyman PR, Versantvoort CHM. Experimental modulation of Mrp (multidrug resistance-associated protein) mediated resistance Eur J Cancer 1996; 32A: 1002-9.
35. Slovak ML, Hoeltge GA, Dalton WS, Trent JM. Pharmacological and biological evidence for differing mechanisms of doxorubicin resistance in two human tumor cell lines. Cancer Res 1988; 48: 2793-7.
36. Cole SPC, Downes HF, Slovak ML. Effect of calcium antagonists on the chemosensitivity of two multidrug resistant human tumour cell lines which do not overexpress P-glycoprotein. Br J Cancer 1989; 59: 42-6.
37. Binaschi M, Supino R, Gambetta RA, et al. MRP gene overexpression in a human doxorubicin-resistant SCLC cell line: alterations in cellular pharmacokinetics and in pattern of cross-resistance Int J Cancer 1995; 62: 84-9.
38. Abe T, Koike K, Ohga T, et al. Chemosensitisation of spontaneous multidrug resistance by a 1,4-dihydropyridine analogue and verapamil in human glioma cell lines overexpressing MRP or MDR1. Br J Cancer 1995; 72: 418-23.
39. Davey RA, Longhurst TJ, Davey MW, et al. Drug resistance mechanisms and MRP expression in response to epirubicin treatment in a human leukaemia cell line. Leuk Res 1995; 19: 275-82.
40. Tasaki Y, Nakagawa M, Ogata J, et al. Reversal by a dihydropyridine derivative of non-P-glycoprotein-mediated multidrug resistance in etoposide-resistant human prostatic cancer cell line. J Urol 1995; 154: 1210-6.
41. Vanhoefer U, Cao S, Minderman H, et al. Pak-104P, a pyridine analogue, reverses paclitaxel and doxorubicin resistance in cell lines and nude mice bearing xenografts that overexpress the multidrug resistance protein. Clin Cancer Res 1996; 2: 369-7.
42. van der Graaf WTA, de Vries EGE, Timmer-Bosscha H, et al. Effects of amiodarone, cyclosporin A, and PSC 833 on the cytotoxicity of mitoxantrone, doxorubicin, and vincristine in non-P-glycoprotein human small cell lung cancer cell lines. Cancer Res 1994; 54: 5368-73.
43. Gekeler V, Boer R, Ise W, et al. The specific bisindolylmaleimide PKC-inhibitor GF 109203X efficiently modulates MRP-associated multiple drug resistance. Biochem Biophys Res Commun 1995; 206: 119-26.
44. Germann UA, Shlyakhter D, Mason VS, et al. Cellular and biochemical characterization of VX-710 as a chemosensitizer: reversal of P-glycoprotein-mediated multidrug resistance in vitro. Anti-Cancer Drugs 1997; 8: 125-40.
45. Marsh W, Sichert D, Center MS. Isolation and characterization of adriamycin-resistant HL-60 cells which are not defective in the initial intracellular accumulation of drug. Cancer Res 1986; 46: 4053-7.
46. McGrath T, Center MS. Adriamycin resistance in HL60 cells in the absence of detectable P-glycoprotein. Biochem Biophys Res Commun 1987; 145: 1171-6.
47. Marquardt D, McCrone S, Center MS. Mechanisms of multidrug resistance in HL60 cells: detection of resistance-associated proteins with antibodies against synthetic peptides that correspond to the deduced sequence of P-glycoprotein. Cancer Res 1990; 50: 1426-30.
48. Krishnamachary N, Center MS. The MRP gene associated with a non-P-glycoprotein multidrug resistance encodes a 190-kDa membrane bound glycoprotein. Cancer Res 1993; 53: 3658-61.
49. Krishnamachary N, Ma L, Zheng L, Safa AR, Center MS. Analysis of MRP gene expression and function in HL60 cells isolated for resistance to adriamycin. Oncol Res 1994; 6: 119-27.
50. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 1981; 41: 1967-72.
51. Twentyman PR, Fox NE, White DJG. Cyclosporin A and its analogues as modifiers of adriamycin and vincristine resistance in a multi-drug resistant human lung cancer cell line. Br J Cancer 1987; 56: 55-7.
52. Sato W, Fukuzawa N, Nakanishi O, et al. Reversal of multidrug resistance by a novel quinoline derivative, MS-209. Cancer Chemother Pharmacol 1995; 35: 271-7.
53. Hyafil F, Vergely C, Duvignaud P, Grandperret T. In vitro and in vivo reversal of multidrug resistance by GF1 20918, an acridonecarboxamide derivative. Cancer Res 1993; 53: 4595-602.
54. Germann UA. Detection of expressed recombinant protein based on multidrug resistance: P-glycoprotein. In: Tuan, RS, ed. Methods in molecular biology. Vol. 63. Expression and detection of recombinant genes. Totowa, NJ: Humana Press 1996: in press.
55. Germann UA, Chambers TC, Ambudkar SV, et al. Characterization of phosphorylation-defective mutants of human P-glycoprotein expressed in mammalian cells. J Biol Chem 1996; 271: 1708-16.
56. Roehm NW, Rodgers GH, Hatfield SM, Glasebrook AL. An improved colorimetric assay for cell proliferation and viability utilizing the tetrazolium salt XTT. J Immunol Methods 1991; 142: 257-65.
57. Feller N, Broxterman HJ, Wahrer DC, Pinedo HM. ATP-dependent efflux of calcein by the multidrug resistance protein (MRP): no inhibition by intracellular glutathione depletion. FEBS Lett 1995; 368: 385-8.
58. Grant CE, Valdimarsson G, Hipfner DR, et al. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res 1994; 54: 357-61.
59. Kruh GD, Chan A, Myers K, et al. Expression complementary DNA library transfer establishes mrp as a multidrug resistance gene. Cancer Res 1994; 54: 1649-52.
60. Versantvoort CH, Withoff S, Broxterman HJ, et al. Resistance-associated factors in human small-cell lungcarcinoma GLC4 sub-lines with increasing adriamycin resistance, Int J Cancer 1995; 61: 375-80.
61. McGrath T, Latoud C, Arnold ST, et al. Mechanisms of multidrug resistance in HL60 cells. Analysis of resistance associated membrane proteins and levels of mdr gene expression. Biochem Pharmacol 1989; 38: 3611-9.
62. Nitiss JL, Beck WT. Antitopoisomerase drug action and resistance. Eur J Cancer 1996; 32A: 958-66.
63. Holló Z, Homoloya L, Hegedüs T, Sarkadi B. Transport properties of the multidrug resistance-associated protein (MRP) in human tumour cells. FEBS Lett 1996; 383:99-104.